Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled TrialThe American journal of psychiatry, 2022-02, Vol.179 (2), p.132-141 [Peer Reviewed Journal]Copyright © 2022 by the American Psychiatric Association 2022 ;Copyright American Psychiatric Association Feb 2022 ;ISSN: 0002-953X ;EISSN: 1535-7228 ;DOI: 10.1176/appi.ajp.2021.20101429 ;PMID: 34711062Full text available |
|
2 |
Material Type: Article
|
A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndromeBlood, 2023-03, Vol.141 (9), p.971-983 [Peer Reviewed Journal]2023 The American Society of Hematology ;2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. ;2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. 2023 The American Society of Hematology ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2022018546 ;PMID: 36399712Full text available |
|
3 |
Material Type: Article
|
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trialEuropean heart journal, 2016-08, Vol.37 (30), p.2406-2413 [Peer Reviewed Journal]Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2016. For permissions please email: journals.permissions@oup.com. ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehw171 ;PMID: 27161611Full text available |
|
4 |
Material Type: Article
|
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2Neurology, 2020-03, Vol.94 (13), p.e1365-e1377 [Peer Reviewed Journal]2020 American Academy of Neurology ;Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. ;Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 2020 American Academy of Neurology ;ISSN: 0028-3878 ;EISSN: 1526-632X ;DOI: 10.1212/WNL.0000000000009169 ;PMID: 32209650Full text available |
|
5 |
Material Type: Article
|
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced MelanomaJournal of clinical oncology, 2023-01, Vol.41 (3), p.528-540 [Peer Reviewed Journal]2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.22.00343 ;PMID: 35998300Full text available |
|
6 |
Material Type: Article
|
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side EffectsThe New England journal of medicine, 2020-11, Vol.383 (22), p.2182-2184 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2031173 ;PMID: 33196154Full text available |
|
7 |
Material Type: Article
|
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1636-1646 [Peer Reviewed Journal]2020 International Association for the Study of Lung Cancer ;Copyright © 2020 by the International Association for the Study of Lung Cancer ;Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. ;ISSN: 1556-0864 ;EISSN: 1556-1380 ;DOI: 10.1016/j.jtho.2020.07.014 ;PMID: 32781263Full text available |
|
8 |
Material Type: Article
|
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized TrialAnnals of Internal Medicine, 2020-10 [Peer Reviewed Journal]2020. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://annals.org/aim/pages/conditions-of-use ;DOI: 10.7326/M20-4207Digital Resources/Online E-Resources |
|
9 |
Material Type: Article
|
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialClinical cancer research, 2020-04, Vol.26 (7), p.1586-1594 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-18-1140 ;PMID: 32034072Full text available |
|
10 |
Material Type: Article
|
Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control TrialThe American journal of gastroenterology, 2020-07, Vol.115 (7), p.1055 [Peer Reviewed Journal]EISSN: 1572-0241 ;DOI: 10.14309/ajg.0000000000000661 ;PMID: 32618656Full text available |
|
11 |
Material Type: Article
|
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe lancet oncology, 2017-09, Vol.18 (9), p.1274-1284 [Peer Reviewed Journal]2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Sep 1, 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30469-2 ;PMID: 28754483Full text available |
|
12 |
Material Type: Article
|
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialintranet 671955 ;ISSN: 1474-547X ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(22)00466-4Full text available |
|
13 |
Material Type: Article
|
Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesThe New England journal of medicine, 2019-10, Vol.381 (18), p.1718-1727 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1908681 ;PMID: 31566307Full text available |
|
14 |
Material Type: Article
|
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast CancerJournal of clinical oncology, 2017-11, Vol.35 (32), p.3638-3646 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.75.6155 ;PMID: 28968163Full text available |
|
15 |
Material Type: Article
|
Mosaic human preimplantation embryos and their developmental potential in a prospective, non-selection clinical trialAmerican journal of human genetics, 2021-12, Vol.108 (12), p.2238-2247 [Peer Reviewed Journal]2021 The Author(s) ;Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. ;2021 The Author(s) 2021 ;ISSN: 0002-9297 ;EISSN: 1537-6605 ;DOI: 10.1016/j.ajhg.2021.11.002 ;PMID: 34798051Full text available |
|
16 |
Material Type: Article
|
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet (British edition), 2021-01, Vol.397 (10269), p.99-111 [Peer Reviewed Journal]2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license ;Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. ;2021. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. This work is published under https://creativecommons.org/licenses/by/3.0/ (theLicense”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2021 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)32661-1 ;PMID: 33306989Full text available |
|
17 |
Material Type: Article
|
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2022-02, Vol.386 (6), p.509-520 [Peer Reviewed Journal]Copyright © 2021 Massachusetts Medical Society. All rights reserved. ;Copyright © 2021 Massachusetts Medical Society. ;2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2116044 ;PMID: 34914868Digital Resources/Online E-Resources |
|
18 |
Material Type: Article
|
Trial of Anifrolumab in Active Systemic Lupus ErythematosusThe New England journal of medicine, 2020-01, Vol.382 (3), p.211-221 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1912196 ;PMID: 31851795Full text available |
|
19 |
Material Type: Article
|
Comparison of protocols and registry entries to published reports for randomised controlled trialsCochrane database of systematic reviews, 2011-01, Vol.2011 (1), p.MR000031-MR000031 [Peer Reviewed Journal]Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.MR000031.pub2 ;PMID: 21249714Full text available |
|
20 |
Material Type: Article
|
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysisEuropean heart journal, 2022-02, Vol.43 (6), p.474-484 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. ;The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. 2021 ;ISSN: 0195-668X ;EISSN: 1522-9645 ;DOI: 10.1093/eurheartj/ehab777 ;PMID: 35023547Full text available |